• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 Next >
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
December 04, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
November 11, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
November 04, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
October 18, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
October 09, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
October 07, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
September 24, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
September 16, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
August 08, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Provides Namodenoson Patent Update
July 29, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
July 17, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
July 11, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
July 01, 2024
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
June 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
June 24, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
June 10, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
June 05, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
May 29, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
May 27, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
May 23, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
May 13, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 09, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 06, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap